HCV Genotype 1 - 6
HCV Subtypes Variants

Genotype 1 and 4 Articles

Genotype 2 and 3 Articles

Genotype 5 and 6 Articles

Genotypes 1 and 4

Hepatitis C Treatment Appears to Be Declining; People with Hard-to Treat Genotypes Are Half as Likely to Receive Therapy
12/01/09

Genotype 1 Chronic Hepatitis C Patients with Low Viral Load Can Achieve Sustained Response with 24 Weeks of Pegylated Interferon plus Ribavirin
11/17/09

InterMune and Roche Begins Trial of Ritonavir-boosted ITMN-191 (RG7227) for Genotype 1 Chronic Hepatitis C Patients
10/06/09

Detectable HCV RNA at Week 8 Is Best Predictor of Relapse in Genotype 1 Hepatitis C Patients Treated with Pegylated Interferon plus Ribavirin
6/23/09

Adding Telaprevir Improves Sustained Response to Pegylated Interferon plus Ribavirin in Genotype 1 Chronic Hepatitis C Patients (PROVE3)
5/05/09

Pegylated Interferon alfa-2a (Pegasys) Relapse Rates in Genotype 1 Chronic Hepatitis C Patients Depend on Weight-based Ribavirin Dosage
4/07/09

Widespread Hepatitis C Treatment Has Led to a Shift in HCV Genotypes in Spain
3/27/2009

Extended Pegylated Interferon plus Ribavirin Therapy Improves Sustained Response Rate in Slow Responder Genotype 1b Hepatitis C Patients
2/03/2009

Genotype 1 HCV Patients with Early but Not Rapid Response May Benefit from 72 Weeks of Pegylated Interferon plus Ribavirin
11/18/2008

Response to Pegylated Interferon plus Ribavirin in Asian Patients with Genotype 1 Chronic Hepatitis C
10/21/2008

24 Weeks of Pegylated Interferon plus Ribavirin May Be Sufficient for Selected Genotype 1/4 Chronic Hepatitis C Patients with Rapid Response
10/14/08

74 Percent of Genotype 1 HCV Patients in Experimental HCV PI Boceprevir Phase II Study Achieve Sustained Virologic Response (SVR) at 48 Weeks
8/05/2008

Adequate Ribavirin Exposure after the First Dose Predicts Sustained Virological Response to Hepatitis C Treatment in Genotype 1 Patients
7/08/08

HCV Genotype 1 Patients with High Viral Load Do Better with 48 vs 24 Weeks of Treatment, despite Rapid Virological Response
7/04/08

Vertex and Tibotec Start Phase 3 Study of Telaprevir for Treatment-Naive Genotype 1 Hepatitis C Patients
3/21/08

Pegylated Interferon plus Ribavirin in the Treatment of Chronic Hepatitis C Genotype 4
1/08/08

Genotypes 2 and 3


Hepatitis C Treatment Appears to Be Declining; People with Hard-to Treat Genotypes Are Half as Likely to Receive Therapy
12/01/09

HCV Genotype 3 May Be Associated with More Rapid Liver Fibrosis Progression in People with Chronic Hepatitis C
10-27-2009

Older Genotype 3 Chronic Hepatitis C Patients Do Not Respond as Well to Interferon-based Therapy
6-16-2009

Reduced Dose and Duration of PegIntron plus Ribavirin Is Not as Effective as Standard Therapy for Genotype 2 and 3 Hepatitis C Patients
5-29-2009

Widespread Hepatitis C Treatment Has Led to a Shift in HCV Genotypes in Spain
3/27/2009

Combination Therapy with Investigational HCV Polymerase Inhibitor R7128 Produces Rapid Response in Patients with Genotype 2/3 HCV
9/12/2008

Body Weight Affects Relapse Rates in Latinos with Genotype 2/3 Hepatitis C Treated with Pegylated Interferon Alfa-2a (Pegasys) plus Ribavirin
8/12/2008

Eight Weeks of Pegylated Interferon plus Ribavirin for Genotype 2 Chronic HCV Patients with Rapid Virological Response (RVR)
8/05/2008

12- Versus 24-week Treatment with Pegylated Interferon plus Ribavirin for Genotype 2 or 3 Chronic Hepatitis C Patients
7/11/08

European Commission Approves Shorter 16-week Course of Pegasys plus Ribavirin for Rapid Responders with HCV Genotypes 2 or 3 and Low Viral Load
7/04/08

Studies Explore Lower Doses of Pegylated Interferon and Ribavirin for People with Hepatitis C Virus Genotypes 2 or 3
7/08/08

Limitations of an 8-week Course of Pegylated interferon plus Ribavirin for Genotype 2 Hepatitis C Patients with Rapid Virological Response
4/24/08

Genetic Variations in HCV Genotype 3 Core Protein Promote Liver Fat Accumulation
2/26/08

Asians with HCV Genotype 3 Do Not Respond as Well as Caucasians to Interferon-based Therapy
2/19/08

HCV Genotypes 2 and 3 Do Not Respond the Same to Interferon-based Treatment
1/29/08

Insulin Resistance Linked to Lower Treatment Response in Genotype 2/3 Patients
2/01/08

Liver Steatosis Is Common in Hepatitis C Patients, Especially Those with Genotype 3
2/01/08

Duration of Pegylated Interferon plus Ribavirin for HCV Genotypes 2 and 3
1/29/08

HCV Genotypes 2 and 3 Do Not Respond the Same to Interferon-based Treatment
1/29/08

Genotypes 5 and 6 Articles
(Genotype 5 - Africa / Genotype 6 - South East Asia)

Hepatitis C Treatment Appears to Be Declining; People with Hard-to Treat Genotypes Are Half as Likely to Receive Therapy
12/01/09

Effectiveness of Pegylated Interferon plus Ribavirin for Chronic Hepatitis C Patients with HCV Genotypes 5 or 6
6-19-2009

Effectiveness of Pegylated Interferon plus Ribavirin for Chronic Hepatitis C Patients with HCV Genotypes 5 or 6
6/19/2009

Widespread Hepatitis C Treatment Has Led to a Shift in HCV Genotypes in Spain
3/27/2009

Individuals with HCV Genotype 6 Respond Well to Pegylated Interferon plus Ribavirin
10/14/08

Epidemiology and Treatment Response of Genotype 5 HCV; Researchers Find New Seventh Genotype
1/27/07

HCV-796 Plus PegIntron Shows Greater Antiviral Activity Across All HCV Genotypes Than Either Agent Used Alone
5/22/07